Cartesian Therapeutics Grants 115,250 Share Options to 4 New Hires
Updated
Updated · GlobeNewswire · Aug 7
Cartesian Therapeutics Grants 115,250 Share Options to 4 New Hires
2 articles · Updated · GlobeNewswire · Aug 7
Summary
Cartesian Therapeutics awarded four new employees options to buy a combined 115,250 shares, with grant dates of Aug. 3 and Aug. 6.
The inducement awards were meant to support recruitment and were issued under Nasdaq Rule 5635(c)(4) through the company’s amended 2018 employment inducement plan.
The options carry exercise prices set at Cartesian’s Nasdaq closing stock price on each grant date, vest over four years, and are scheduled to be fully vested by August 2030.
Cartesian, a late clinical-stage biotech focused on autoimmune diseases, is advancing lead CAR-T candidate Descartes-08 in Phase 3 for generalized myasthenia gravis and in earlier-stage studies for other indications.